Article Sidebar

pdf
Date Published: 14/07/2024
Abstract Views: 229
Views pdf: 44
DOI: https://doi.org/10.51298/vmj.v540i2.10358
Issue
Vol. 540 No. 2 (2024)
Section
Các bài báo
How to Cite
Nguyễn, V. T., Nguyễn, V. P., & Ngô, K. T. (2024). EFFECTIVENESS OF HIGH-FLOW NASAL CANNULA OXYGEN THERAPY (HFNC) ON SEVERE COVID 19 PATIENTS. Vietnam Medical Journal, 540(2). https://doi.org/10.51298/vmj.v540i2.10358

EFFECTIVENESS OF HIGH-FLOW NASAL CANNULA OXYGEN THERAPY (HFNC) ON SEVERE COVID 19 PATIENTS

Vũ Trung Nguyễn, Việt Phương Nguyễn, Kiều Trang Ngô

Main Article Content

Abstract

Objectives: To evaluate the effectiveness of the high-flow nasal cannula (HFNC) therapy and some factors related to treatment outcomes on severe Covid 19 patients. Methods: A longitudinal- interventional study, on 50 severe Covid 19 patients  admitted to the 5G Field Hospital – Vietnam Military Medical Academy from September 1, 2021 to October 31, 2021. Results: The success rate with HFNC therapy in patients with severe Covid 19 was 68.0%.  HFNC therapy improved clinical features and arterial blood gas parameters after 48 hours of intervention, the differences were all statistically significant with p < 0.05. Clinical improvements, heart rate decreased (100.8 vs. 85.1), respiratory rate decreased (27.9 vs. 22.1), SpO2 increased (89.0 vs. 95.3 ), ROX score decreased (3.75 vs. 7.69) and Borg dyspnea score decreased (3.57 vs. 2.28). Improvements in arterial blood gas parameters, PaO2 increased (78.82 vs 88.09), PaCO2 decreased (44.15 vs 37.93) and PO2/FiO2 increased (176, 43 vs. 239.46). The group that failed HFNC therapy had a higher age ratio and a lower ROX score at the 6-hour follow-up time point than the successful group (p < 0.05). Conclusion: HFNC is effective in reducing the risk of intubation and noninvasive ventilation, improving clinical characteristics and arteria blood gas parameters in patients with severe Covid 19 infection. Age and ROX score related to the prognosis of response to HFNC therapy.

Article Details

Keywords

Severe Covid 19, High-flow nasal cannula (HFNC) oxygen therapy

References

1. Bell N., Hutchinson C. L., Green T. C., et al. (2015). Randomised control trial of humidified high flow nasal cannulae versus standard oxygen in the emergency department. Emerg Med Australas, 27 (6), 537-541.
2. Arruda D. G., Kieling G. A., Melo-Diaz L. L. (2023). Effectiveness of high-flow nasal cannula therapy on clinical outcomes in adults with COVID-19: A systematic review. Can J Respir Ther, 59, 52-65.
3. Saffarini L., Sabobeh N., Lasfer C., et al. (2024). High-Flow Nasal Cannula in COVID-19 Patients With Moderate to Severe Respiratory Distress: A Retrospective Analysis. Cureus, 16 (1)
4. Bộ Y tế (2021). Hướng dẫn chẩn đoán và điều trị COVID-19. Quyết định số 4689/QĐ-BYT ngày 6/10/2021,
5. Khan M. S., Prakash J., Banerjee S., et al. (2022). High-flow Nasal Oxygen Therapy in COVID-19 Critically Ill Patients with Acute Hypoxemic Respiratory Failure: A Prospective Observational Cohort Study. Indian J Crit Care Med, 26 (5), 596-603.
6. Trần Thanh Lê, Đỗ Ngọc Sơn, Đỗ Quốc Chính (2022). Hiệu quả của thở oxy làm ẩm dòng cao qua Canuyn mũi trên bệnh nhân đợt cấp bệnh phổi tắc nghẽn mạn tính. Tạp Chí Y Học Việt Nam, số 1A.
7. Li Y., LI C., Chang W., et al. (2023). High-flow nasal cannula reduces intubation rate in patients with COVID-19 with acute respiratory failure: a meta-analysis and systematic review. BMJ Open, 13 (3), e067879.
8. Hu M., Zhou Q., Zheng R., et al. (2020). Application of high-flow nasal cannula in hypoxemic patients with COVID-19: a retrospective cohort study. BMC Pulm Med, 20 (1), 324.